Thank you everyone. hello Jed and
As happy in from to call clinical with provide you side. the always, updates today's I am participate and
progress complete arm are in I RA. to as we are that have that pleased Phase both through our with two one announce and enrollment this Current arms completed the running this trial scheduled. will three. more am trial will on currently year I recruitment projections So begin than of in and this in Xb halfway trial
imaging enable order and reproducibility RA. in help study in the obtain active one data calculations power our both healthy you repeatability, stability and the with arm, to might tilmanocept our X. arms subjects third and recall, our Phase we we validate mirroring to for are And to us patients Phase X two, readout in the of in are In upcoming evaluating
were both over positive, previously, As the two low of very on and results the interim first arms announced day imaging, time. demonstrating variability within
RA can product active stable, in without into involved and and is robust, controls this and with define quantitative patients a provide This can important joints Those our successful inflammation. data reproducible advancing that RA. that in imaging imaging technology demonstrated with fundamentally tilmanocept in RA healthy is and to
on an written have the presentation submitted first We conference. an interim results and of analysis abstract international it for at the
interim at arm the the data. three The next look is milestone
wait to three arm of imaging been their until initiation event therapy. post has plan half at of second about the subjects anti-TNF five had weeks Our
We image on acquired those sets to way and to weeks. are well this the next be milestone expect coming in our
We therapy idea will post then complete of analysis these of in and of to we magnitude expect five RA scan have the to from data might baseline an weeks change subjects. start see
moving give our are per and evidence as that our to sure possible is you make recruitment in months in high principal provide while This and to about and efficiently specific here and who recruitment that North rate. diligently subjects to to Evidence of team about in X rates investigator. One a level. a things trials suggests the of site and X.X it Western let want America literally data in know night and recruit typical subject one to for performing that to X clinical good trial keep example worked credit month order Phase RA two-and-a-half Europe in as these means rapidly for to takes quality per typically integrity you is maintaining team day I at trials.
protocol subjects that all three site, in can so large of complete arm before to difficult that X.X so that we on With times designs. arm across and arm are per X.X rate has efficient enrolling And Our trial Jed is a both one three about pharma recruitment last companies, into RA trials that we compared small. are lean is significantly to other typical month. too obviously alluded rate several relatively month rate actually recruit RA with into we at optimistic the rate the but in and many much per and site enrollment as three And per across increased current our of team that trial per a long. months, a our to, that
and the with to the the enroll into from planning for histopathology of this three as joints patients comparative imaging Xb of RA our continue well We arm readout X. trial Phase to the Phase of study of start will as are
currently the X ongoing into be right sites well that trial. most are will positioned We Phase Xb for rolled are that into the the of recruiting since Phase
and And strategies for will recruitment established. so logistics the be
comparative to subjects have principal patients quarter. investigator, in tissue in This that where biopsy network the enroll will Our is our where in that imaging a leading is also academic world's of in U.K. with current specialists and primarily Xb the the domain. located of Phase study histopath upcoming is study synovial centers this to plan RA initiate physician there
well. site least one U.S. at We in the as will have
We have begin. way place our to and to many in all and spent initiate are trial approvals to well this contracts having on needed months preparing
also while approval would and Phase FDA we while have finishing made financial Phase out that resources Xb current to start this the isn't Recall that pushed trial it We beginning trial this run for adequately, required we indications RA we the with have the Phase initial well up the is we trials X. possible in Xb of of in partners going RA believe it to CDXXX but the biomarker as critical engage order pharma its new as as of achieve to in a qualification in for that use their RA therapeutics. for for sure are
first this so be objectives with aligned sure FDA one are time and X the later fully patient, interim visit we for at happen begin results be Phase our in ready following Phase targets can X to first is that this hand and the the meeting Our two with plan and analysis we to should year. on
and been method We healthy joints determining subjects tilmanocept of for in the patients of our have amount quantitative to refine RA. with the also of working further both localization
foundation our our originally our had developed in the as key as both readout well a As interim At our Phase modified evaluated analysis, we we and method RA rest. and running was upon for you the of of the as significant the results. time the is following know, believe that from the proposed in the which method it prior It method looked trial this method we all study first preparation refine X made to the in have best rolling Phase the in. We with we modified new will all improvements continue currently X. data analysis at provided data indications
to the an application converted application. related AX we so-called recently Directly uptake value to patent tilmanocept this, provisional
lowest As newly is the quantitative methodology. quantitation variability, part of The in to significant our discovered claims provide this read the most imaging possible. made of revisions improvements we method robust the with original to to optimize goal, conversion, course,
we of Sarcoma. in indications, other patient enrollment funded NIH completed all have In our imaging subjects and in study Kaposi's now
safety in subcutaneous we the sought tilmanocept with study's this and injection title, to perform of trial to the in diagnosed comparison injection outlined As HIV patients evaluate of escalating KS. a doses in IV by
technology receptor that might targets. KS cells the You recall CDXXX that express our
on has therapeutics both as in a it so pursue well it well and makes Africa. HIV-infected an And particular, the the both as throughout as perspective, sense people, indication perspective in from U.S. as to continued a as diagnostic imaging it impact
We and site in seen have and and was detected is injection read results. had out have No comparison Final will trial injection our to of lymphatics. shortly. subcu Qualitatively, biopsy patients the excellent a are visualization localization waiting close signal lesions we take completed of final this locked in database safety to place IV and we of as imaging these KS clinical what planned. assessment of the
up, hope on the discussion Following to long. with before open wrap we path full KS FDA in about an up too to sNDA analysis
have we investigator-initiated to we Grinspoon there continuing in look run study at Dr. ability also atherosclerotic for We the at this provided funds supportive to the Boston. imaging tilmanocept plaque This macrophages. MGH of that of study published is control. is Scores evidence to building HIV-infected upon Framingham activated detect with patients Risk work and them in provided the supportive already healthy matched plaques this with that enriched
team regular in his and the looking discussions him they different have at update administration. milestone and completed We internal routes have of imaging an results study via with
background with published excellent The so-called aortas hypothesis data are an soft line supportive of in seen these of of the plaque to that tilmanocept we read work and can patients. have provide in the the earlier signal
support next we will We these might And studies. we indications is discuss. have request outline possible on internal finalized, with Once for to are disease well plan our look like. cardiovascular meeting specific to trial partners engaged as with discussions and in trial having the help the external FDA what what a to go
with imaging have the of work This at we Preclinical studies looking of at grant ongoing NHLBI in XX collaboration have of set. support aligns, we Birmingham, received course, PET the the that for plaques. data recently tilmanocept Alabama University Gallium we also with and of are Phase X our with first the
FDG agent As in release PET method to macrophages this, imaging, significant has in will and we but as this fits project deficiencies pipeline and of it which widely believe FXX us compare one outlined to looking to PET a plaque, our imaging about we with in our a studied atherosclerosis existing which test press comparison tilmanocept enable at of and tilmanocept. is
of have the On the between have preclinical had with. company clinical-stage Remember, we the plans side, research that to purpose agreement companies kickoff to and immuno-oncology collaborative proprietary study the about combinatory collaboration along Based Along announced discussions with our therapeutic with in recently possible having collaboration in we begin our with place studies preclinical effect two players IMV, our is our meeting for conduct discussions their are of this first research space activating expect the other the our T-cell therapeutics macrophage to compounds I evaluate targeting on good with we shortly. activated IMV, would study those lines, efforts. platform. the
and significant then construct towards in studies. human we reproducible grant, have scalable Using tested a synthesizing be funding therapeutic NIH therapeutics from can robust, made that our steps
made generation for and of We molecule we of provide have improvement making diagnostic the that also next in will in therapeutic certain applications. significant our think strides
We our mechanism this culture doxorubicin results positive containing pre-IND hold have meeting and cell our also FDA of to a in the we received preclinical studies and aim in with models from year. action construct of
for We as this covering expect submit publication year synthesis action well as work. of mechanism these manuscripts to studies the
month, This an patent AX therapeutic be patent another application, a in converting this will to application. provisional case we
least We year in at expect synthesis. new on to patent file application this chemical improvements one provisional
dexamethasone Finally, initiated constructs new therapeutic work and also we have doxorubicin. payloads with other on than
progress to other of touch to FDA, moving and this and we through diagnostic the quarter we that continue the some We indications. just largely update. therapeutic push submission pipeline remain on last focused are that for on highlights those wanted on support the of So to RA towards our the while and
As collaborators and achieve sites of CEO, to and work. academic for team the to our always, these hard their the I network keep things goals space efforts opportunity their Thank all moving, for want tireless research of allowing us to here and our trial Jed, you. clinical thank for
Now call Jed. turn the I like would to to over back
